Safety and Tolerability of Medications for ADHD

Pharmacovigilance in Psychiatry

Volumn , Issue , 2016, Pages 233-251

  Clavenna, Antonio ^a   Bonati, Maurizio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Amphetamines; Atomoxetine; Attention deficit hyperactivity disorder; Methylphenidate

Indexed keywords

EID: 84989231103     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-24741-0     Document Type: Chapter

References (65)

1. Aagaard L, Hansen EH (2010) Adverse drug reactions from psychotropic medicines in the paediatric population: analysis of reports to the Danish medicines agency over a decade. BMC Res Notes 3:176
2. Aagaard L, Hansen EH (2011) The occurrence of adverse drug reactions reported for attention defi cit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies. Neuropsychiatr Dis Treat 7:729-744
3. American Academy of Pediatrics (2011) ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-defi cit/hyperactivity disorder in children and adolescents. Pediatrics 128:1007-1022
4. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders: DSM-5, 5th edn. American Psychiatric Publishing, Washington, DC
5. Bangs ME, Tauscher-Wisniewski S, Polzer J et al (2008) Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 47:209-218
6. Bangs ME, Wietecha LA, Wang S, Buchanan AS, Kelsey DK (2014) Meta-analysis of suiciderelated behavior or ideation in child, adolescent, and adult patients treated with atomoxetine. J Child Adolesc Psychopharmacol 24:426-434
7. Becker SP, Luebbe AM, Langberg JM (2012) Co-occurring mental health problems and peer functioning among youth with attention-defi cit/hyperactivity disorder: a review and recommendations for future research. Clin Child Fam Psychol Rev 15:279-302
8. Biederman J, Spencer TJ, Monuteaux MC, Faraone SV (2010) A naturalistic 10-year prospective study of height and weight in children with attention-defi cit hyperactivity disorder grown up: sex and treatment effects. J Pediatr 157:635-640, 640
9. Blake KV, Zaccaria C, Domergue F et al (2014) Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: implications for pharmacovigilance. Paediatr Drugs 16:309-319
10. Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF (2009) Meta-analysis: treatment of attention-defi cit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 48:884-893
11. Capuano A, Scavone C, Rafaniello C et al (2014) Atomoxetine in the treatment of attention defi cit hyperactivity disorder and suicidal ideation. Expert Opin Drug Saf 13(Suppl 1):S69-S78
12. Chen MH, Su TP, Chen YS et al (2013) Asthma and attention-defi cit/hyperactivity disorder: a nationwide population-based prospective cohort study. J Child Psychol Psychiatry 54:1208-1214
13. Chen Q, Sjolander A, Runeson B et al (2014) Drug treatment for attention-defi cit/hyperactivity disorder and suicidal behaviour: register based study. BMJ 348:g3769
14. Cheng JY, Chen RY, Ko JS, Ng EM (2007) Effi cacy and safety of atomoxetine for attention-defi cit/ hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacol (Berl) 194:197-209
15. Clavenna A, Bonati M (2009) Adverse drug reactions in childhood: a review of prospective studies and safety alerts. Arch Dis Child 94:724-728
16. Clavenna A, Bonati M (2014) Safety of medicines used for ADHD in children: a review of published prospective clinical trials. Arch Dis Child 99:866-872
17. Coghill DR, Caballero B, Sorooshian S, Civil R (2014) A systematic review of the safety of lisdexamfetamine dimesylate. CNS Drugs 28:497-511
18. Cohen-Zion M, Ancoli-Israel S (2004) Sleep in children with attention-defi cit hyperactivity disorder (ADHD): a review of naturalistic and stimulant intervention studies. Sleep Med Rev 8:379-402
19. Cooper WO, Habel LA, Sox CM et al (2011) ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 365:1896-1904
20. Cortese S, Faraone SV, Konofal E, Lecendreux M (2009) Sleep in children with attention-defi cit/ hyperactivity disorder: meta-analysis of subjective and objective studies. J Am Acad Child Adolesc Psychiatry 48:894-908
21. Cortese S, Holtmann M, Banaschewski T et al (2013) Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry 54:227-246
22. De Crescenzo F, Armando M, Mazzone L et al (2014) The use of actigraphy in the monitoring of methylphenidate versus placebo in ADHD: a meta-analysis. Atten Defi c Hyperactivity Disord 6:49-58
23. Donnelly C, Bangs M, Trzepacz P et al (2009) Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 48:176-185
24. Food and Drug Administration (2013) Methylphenidate ADHD medications: drug safety communication - risk of long-lasting erections. http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm378876.htm?source=gov delivery&utm_medium=email&utm_source=govdelivery
25. Dunn DW, Austin JK, Perkins SM (2009) Prevalence of psychopathology in childhood epilepsy: categorical and dimensional measures. Dev Med Child Neurol 51:364-372
26. Elia J, Ambrosini P, Berrettini W (2008) ADHD characteristics: I. Concurrent co-morbidity patterns in children & adolescents. Child Adolesc Psychiatry Ment Health 2:15
27. Faraone SV, Biederman J, Morley CP, Spencer TJ (2008) Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry 47:994-1009
28. Findling RL, Wigal SB, Bukstein OG et al (2009) Long-term tolerability of the methylphenidate transdermal system in pediatric attention-defi cit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. Clin Ther 31:1844-1855
29. Gillberg C, Gillberg IC, Rasmussen P et al (2004) Co-existing disorders in ADHD - implications for diagnosis and intervention. Eur Child Adolesc Psychiatry 13(Suppl 1):I80-I92
30. Gould MS, Walsh BT, Munfakh JL et al (2009) Sudden death and use of stimulant medications in youths. Am J Psychiatry 166:992-1001
31. Graham J, Coghill D (2008) Adverse effects of pharmacotherapies for attention-defi cit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs 22:213-237
32. Graham J, Banaschewski T, Buitelaar J et al (2011) European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 20:17-37
33. Habel LA, Cooper WO, Sox CM et al (2011) ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 306:2673-2683
34. Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE (2011) Cardiovascular risk of stimulant treatment in pediatric attention-defi cit/hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatry 50:978-990
35. Hammerness PG, Karampahtsis C, Babalola R, Alexander ME (2015) Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks? Expert Opin Drug Saf 14:543-551
36. Harfterkamp M, Buitelaar JK, Minderaa RB et al (2013) Long-term treatment with atomoxetine for attention-defi cit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study. J Child Adolesc Psychopharmacol 23:194-199
37. Harstad EB, Weaver AL, Katusic SK et al (2014) ADHD, stimulant treatment, and growth: a longitudinal study. Pediatrics 134:e935-e944
38. Hawcutt DB, Mainie P, Riordan A, Smyth RL, Pirmohamed M (2012) Reported paediatric adverse drug reactions in the UK 2000-2009. Br J Clin Pharmacol 73:437-446
39. Hesdorffer DC, Ludvigsson P, Olafsson E et al (2004) ADHD as a risk factor for incident unprovoked seizures and epilepsy in children. Arch Gen Psychiatry 61:731-736
40. Hirota T, Schwartz S, Correll CU (2014) Alpha-2 agonists for attention-defi cit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry 53:153-173
41. Hoare P, Remschmidt H, Medori R et al (2005) 12-month effi cacy and safety of OROS MPH in children and adolescents with attention-defi cit/hyperactivity disorder switched from MPH. Eur Child Adolesc Psychiatry 14:305-309
42. Humphreys KL, Eng T, Lee SS (2013) Stimulant medication and substance use outcomes: a metaanalysis. JAMA Psychiatry 70:740-749
43. Impey M, Heun R (2012) Completed suicide, ideation and attempt in attention defi cit hyperactivity disorder. Acta Psychiatr Scand 125:93-102
44. Kratochvil CJ, Wilens TE, Greenhill LL et al (2006) Effects of long-term atomoxetine treatment for young children with attention-defi cit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:919-927
45. Lee WJ, Lee TA, Pickard AS, Caskey RN, Schumock GT (2014) Drugs associated with adverse events in children and adolescents. Pharmacotherapy 34:918-926
46. McAfee AT, Holdridge KC, Johannes CB, Hornbuckle K, Walker AM (2008) The effect of pharmacotherapy for attention defi cit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims database. Curr Drug Saf 3:123-131
47. McGough JJ, Biederman J, Wigal SB et al (2005) Long-term tolerability and effectiveness of oncedaily mixed amphetamine salts (Adderall XR) in children with ADHD. J Am Acad Child Adolesc Psychiatry 44:530-538
48. Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R (2009) Hallucinations and other psychotic symptoms associated with the use of attention-defi cit/hyperactivity disorder drugs in children. Pediatrics 123:611-616
49. National Collaborating Centre For Mental Health (2008) Attention defi cit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. NICE, London
50. Ruggiero S, Clavenna A, Reale L et al (2014) Guanfacine for attention defi cit and hyperactivity disorder in pediatrics: a systematic review and meta-analysis. Eur Neuropsychopharmacol 24:1578-1590
51. Schachter HM, Pham B, King J, Langford S, Moher D (2001) How effi cacious and safe is shortacting methylphenidate for the treatment of attention-defi cit disorder in children and adolescents? A meta-analysis. CMAJ 165:1475-1488
52. Schelleman H, Bilker WB, Strom BL et al (2011) Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics 127:1102-1110
53. Schwartz S, Correll CU (2014) Effi cacy and safety of atomoxetine in children and adolescents with attention-defi cit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry 53:174-187
54. Schwartz BS, Bailey-Davis L, Bandeen-Roche K et al (2014) Attention defi cit disorder, stimulant use, and childhood body mass index trajectory. Pediatrics 133:668-676
55. Simpson HA, Jung L, Murphy TK (2011) Update on attention-defi cit/hyperactivity disorder and tic disorders: a review of the current literature. Curr Psychiatry Rep 13:351-356
56. Star K, Noren GN, Nordin K, Edwards IR (2011) Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase. Drug Saf 34:415-428
57. Stein MA, Weiss M, Hlavaty L (2012) ADHD treatments, sleep, and sleep problems: complex associations. Neurotherapeutics 9:509-517
58. Thomas R, Sanders S, Doust J, Beller E, Glasziou P (2015) Prevalence of attention-defi cit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics 135(4):e994-e1001
59. Vaughan B, Kratochvil CJ (2012) Pharmacotherapy of pediatric attention-defi cit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 21:941-955
60. Wernicke JF, Faries D, Girod D et al (2003) Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 26:729-740
61. Wilens T, Pelham W, Stein M et al (2003) ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 42:424-433
62. Wilens T, McBurnett K, Stein M et al (2005) ADHD treatment with once-daily OROS methylphenidate: fi nal results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 44:1015-1023
63. Wilens TE, Gignac M, Swezey A, Monuteaux MC, Biederman J (2006) Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 45:408-414
64. Willcutt EG (2012) The prevalence of DSM-IV attention-defi cit/hyperactivity disorder: a metaanalytic review. Neurotherapeutics 9:490-499
65. Zulauf CA, Sprich SE, Safren SA, Wilens TE (2014) The complicated relationship between attention defi cit/hyperactivity disorder and substance use disorders. Curr Psychiatry Rep 16:436